Evidence map›Paper›PMID 38249159›Full record

ReviewFrontiers in radiology2023

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy.

Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Zahra Saadatpour, C Austin Wheeler, Marissa Natelson Love, Manoj Tanwar

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Houman SotoudehDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Mohammadreza AlizadehPhysiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Ramin ShahidiSchool of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.
Parnian ShobeiriDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Zahra SaadatpourDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
C Austin WheelerDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Marissa Natelson LoveDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL, United States.
Manoj TanwarDepartment of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States.
University of Alabama at Birmingham · USBushehr University of Medical Sciences · IRIran University of Medical Sciences · IRMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification. Recently, AD research has begun to shift focus towards disease-modifying therapies that can alter the progression of AD. In this context, a class of immunotherapy agents known as monoclonal antibodies target diverse cerebral amyloid-beta (Aβ) epitopes to inhibit disease progression. Aducanumab was authorized by the US Food and Drug Administration (FDA) to treat AD on June 7, 2021. Aducanumab has shown promising clinical and biomarker efficacy but is associated with amyloid-related imaging abnormalities (ARIA). Neuroradiologists play a critical role in diagnosing ARIA, necessitating familiarity with this condition. This pictorial review will appraise the radiologic presentation of ARIA in patients on aducanumab.

Indexed as

aducanumabAlzheimer’s diseaseamyloid related imaging abnormalitiesanti amyloid aggregationneuroimaging

Identifiers

PMID38249159
PMCPMC10796528
OpenAlexW4390610707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.